Bone loss linked to the usage of Anastrozole partially reverses, particularly at the lumbar spine, after stopping treatment.
Anastrozole is a hormone treatment recommended by NICE to prevent breast cancer in high-risk postmenopausal women.
The results, published in the British Journal of Cancer, are from a sub-study of 1,410 women from the International Breast cancer Intervention Study (IBIS-II) which investigated bone density in women who had completed anastrozole treatment.
Lead author Ivana Sestak from Queen Mary University of London said: "Overall, anastrozole-related bone loss seems to be manageable. Any risk to bone health should be weighed against overall efficacy and tolerability for the preventive treatment of at high-risk women.
This knowledge will help physicians and women who are eligible to take this drug to have a full picture of its effects, so that risks and benefits can be discussed in the decision-making process."